


## Sartorius Stedim India on expansion mode

08 July 2009 | News



## Sartorius Stedim India on expansion mode

Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves.

Image not found the rear santomus Group is an internationally renowned Germany-based laboratory and process technology provider covering biotechnology and mechatronics. Sartorius Stedim Biotech is one of the leading providers of cutting-edge equipments and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop

and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Key Sartorius customers are from the pharmaceutical, chemical and food and beverage industries and from numerous research and educational institutes of the public sector. The company employs approximately 2,300 people globally.

Through its presence in India, Sartorius brings all the expertise of Sartorius group to its Indian customers apart from adding value through quality manufacturing of engineered systems both in biotechnology and mechatronics. The Indian manufacturing operations cover all aspects of Sartorius business like flat filters, standard and customized engineered systems, R&D. It exports its products and components to group companies in Germany and other Asian countries.

Sartorius Stedim India has invested €5 million in a spanking new integrated facility in Bangalore that will house state-of-theart manufacturing. It has already started operations in its new R&D facility which covers cell culture, microbiology, process development studies and filter validation studies.

Sartorius is making a substantial expansion of its technology portfolio in the area of single-use bioreactors. The company is bringing out two prototypes of innovative single-use bioreactors that operate based on novel mixing technologies. These cell culture systems were developed in cooperation with the German company Bayer Technology Services (BTS) and the Swiss cell culture specialist ExcellGene. The new bioreactors have been specially designed for the manufacture of monoclonal antibodies, recombinant proteins and vaccines.

In 2010, the company plans to extend its technology portfolio by two further systems: a rotationally oscillating bioreactor and an orbital shake bioreactor. Each of these four agitation technologies offers users specific advantages contingent upon the cells to be produced, the scale-up level of the cell cultures and additional process parameters.